Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions ...

Imagine a gem hunter facing a vast and uncharted landscape to uncover a single beautiful diamond. It is a bit like drug discovery. Scientists create and evaluate hundreds and thousands of molecules in ...

A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, ...

With just the click of a button on your smartphone, you can order virtually anything and have it on your doorstep in one or ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

NCBiotech and their coalition of partners received a $25 million Phase 2 award from the U.S. Economic Development Administration’s Build Back Better Regional Challenge. This award will further ...

No drug is free from risks, and no two human anatomies are completely identical (meaning different individuals can face different risks), but from a real-world patient perspective — anecdotally — the ...